The Effect of Tranexamic Acid on Calculated Total Blood Loss in Anticoagulated patients undergoing Total Shoulder Arthroplasty

Brief description of study

The purpose of this research study is to compare how well Tranexamic Acid (TXA) reduces total blood loss, surgical drain output (fluids released at the site of surgery) and hematoma (collection of blood outside the vessels) formation in patients who take blood thinner medications prior to undergoing total shoulder replacement. Tranexamic Acid (TXA) is a medication that slows or stops the breakdown of blood clots. It is Food and Drug Administration (FDA) approved for short-term use in people with hemophilia (an inherited condition where the blood doesn’t form clots) and for preventing or reducing excessive bleeding following tooth extraction (surgical removal).


Clinical Study Identifier: s20-00803
ClinicalTrials.gov Identifier: NCT04560010
Principal Investigator: Uchenna O Umeh.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.